Not applicableStudy completedNCT03955588What this trial is testingReplacement of Cytogenetics by aCGH in Prenatal DiagnosisWho this might be right forPrenatal Diagnosis The University of Hong Kong 51
Testing effectiveness (Phase 2)Looking for participantsNCT05735717What this trial is testingMT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesWho this might be right forHematologic MalignancyAcute LeukemiaRemission+21 more Masonic Cancer Center, University of Minnesota 70
Not applicableStudy completedNCT00579930What this trial is testingCytogenetic and Molecular Genetic Studies in Bone SarcomasWho this might be right forLung Cancer Memorial Sloan Kettering Cancer Center 1
Early research (Phase 1)Not Yet RecruitingNCT07114432What this trial is testingRN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple MyelomaWho this might be right forNewly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM) Tianjin Medical University Cancer Institute and Hospital 19
Large-scale testing (Phase 3)Ended earlyNCT00519090What this trial is testingNilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Who this might be right forMyelogenous Leukemia Novartis Pharmaceuticals 6
Not applicableUnknownNCT00064597What this trial is testingNoninvasive Prenatal Diagnosis: Using Fetal Cells From Maternal BloodWho this might be right forChromosome Disorders Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 3,500
Testing effectiveness (Phase 2)Ended earlyNCT01570868What this trial is testingPonatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)Who this might be right forLeukemia M.D. Anderson Cancer Center 51
Large-scale testing (Phase 3)UnknownNCT00297570What this trial is testingImatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib TherapyWho this might be right forLeukemia, Myeloid, Philadelphia-Positive Sheba Medical Center 90
Post-approval studies (Phase 4)Ended earlyNCT01198054What this trial is testingLENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)Who this might be right forAML PETHEMA Foundation 4
Not applicableStudy completedNCT01426308What this trial is testingMethod Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality TestWho this might be right forPost-natal Cytogenetics Illumina, Inc. 900
Testing effectiveness (Phase 2)Looking for participantsNCT07109323What this trial is testingAutologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MMWho this might be right forUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High RiskPrimary Refractory+4 more Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)UnknownNCT00704704What this trial is testingSafety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)Who this might be right forMyelodysplastic Syndrome Tel-Aviv Sourasky Medical Center 50
Testing effectiveness (Phase 2)Study completedNCT00915785What this trial is testingAzacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic AbnormalitiesWho this might be right forMyelodysplastic SyndromesLeukemia, Myeloid, Acute King's College London 40
Testing effectiveness (Phase 2)UnknownNCT02885766What this trial is testingStudy to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL GeneWho this might be right forChronic Myeloid LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive Fusion Pharma LLC 65
Testing effectiveness (Phase 2)Ended earlyNCT00210119What this trial is testingImatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular ResponseWho this might be right forMyeloid Leukemia, Chronic Institut Bergonié 19
Testing effectiveness (Phase 2)Study completedNCT01081431What this trial is testingSafety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5qWho this might be right forMyelodysplastic Syndromes Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 91
Testing effectiveness (Phase 2)Study completedNCT00858806What this trial is testingIntermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib TherapyWho this might be right forChronic Myeloid Leukemia Università degli Studi di Brescia 78
Testing effectiveness (Phase 2)Study completedNCT00045422What this trial is testingInterferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaWho this might be right forLeukemia Memorial Sloan Kettering Cancer Center
Not applicableStudy completedNCT05900076What this trial is testingTechnical Feasibility of the cfDNA Test for Non-invasive Cytogenetic Analysis of Early Miscarriages Versus the Gold Standard MicroarrayWho this might be right forSpontaneous Miscarriage Hospices Civils de Lyon 78
Testing effectiveness (Phase 2)WithdrawnNCT03000634What this trial is testing2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyWho this might be right forMultiple Myeloma University of Arkansas